ABVC BioPharma Inc

NASDAQ:ABVC  
0.89
+0.01 (+1.15%)
Products, Regulatory

ABVC Biopharma provides Vitargus® update

Published: 08/18/2022 12:39 GMT
ABVC BioPharma Inc (ABVC) - Abvc Biopharma Provides Vitargus® Update.
Abvc Biopharma Inc - Phase Ii Vitargus® Clinical Trial Receives Local Ethics Committee Approval in Thailand.
Abvc Biopharma - in Parallel, Vitargus Phase Ii Study Protocol Documents Have Been Submitted to Australian Bellberry Human Research Ethics Committee.
Abvc Biopharma - Both Hospitals Now Expect to Receive a Thai FDA Investigational Product (ip) Import License Within Next 30 Days.
Abvc - Upon Approval by Hrec, Co Will Submit Application to Australian Therapeutic Goods Administration (tga) for Clinical Trial Notification of Study.
Abvc Biopharma Inc - Expect to Begin Clinical Trials in Other Asia-pacific Countries Before End of 2022 for Vitargus.